Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -4.34 is 43% above its 5-year average of -7.67, near the high end of its 5-year range (-29.55–-2.70).
23.30% below its 12-month average of -3.52.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.95.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-4.34
EARNINGS PER SHARE (EPS) AVG TTM
-3.52
EARNINGS PER SHARE (EPS) AVG 3Y
-3.45
EARNINGS PER SHARE (EPS) AVG 5Y
-7.67
EARNINGS PER SHARE (EPS) AVG 10Y
-195.05
EARNINGS PER SHARE (EPS) AVG 15Y
-517.99
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-23.30%
CURRENT VS 3Y AVG
-25.89%
CURRENT VS 5Y AVG
+43.44%
CURRENT VS 10Y AVG
+97.77%
CURRENT VS 15Y AVG
+99.16%
CURRENT VS 20Y AVG
N/A
Atossa Therapeutics, Inc.
Market Cap
$25.19M
Earnings Per Share (EPS)
-4.34
TTM Avg
-3.52
3Y Avg
-3.45
5Y Avg
-7.67
Market Cap
$24.86M
Earnings Per Share (EPS)
N/A
TTM Avg
22.45
3Y Avg
9.70
5Y Avg
5.59
Market Cap
$25.10M
Earnings Per Share (EPS)
-0.29
TTM Avg
-0.41
3Y Avg
-1.95
5Y Avg
-2.99
Market Cap
$22.80M
Earnings Per Share (EPS)
-32.78
TTM Avg
-24.95
3Y Avg
-26.53
5Y Avg
-21.18
Market Cap
$29.10M
Earnings Per Share (EPS)
-2.41
TTM Avg
-9.11
3Y Avg
-20.57
5Y Avg
-19.82
Market Cap
$28.20M
Earnings Per Share (EPS)
-4.31
TTM Avg
-4.75
3Y Avg
-350.99
5Y Avg
-43000.60
Market Cap
$22.22M
Earnings Per Share (EPS)
-1.66
TTM Avg
-1.66
3Y Avg
-2.82
5Y Avg
-25.82
Market Cap
$28.70M
Earnings Per Share (EPS)
-0.62
TTM Avg
-0.83
3Y Avg
-1.05
5Y Avg
-1.29
Market Cap
$30.00M
Earnings Per Share (EPS)
-3.21
TTM Avg
-2.50
3Y Avg
-4.25
5Y Avg
-9.67
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atossa Therapeutics, Inc. (ATOS) | $25.19M | -4.34 | -3.52 | -3.45 | -7.67 |
| Kyntra Bio, Inc. (KYNB)vs › | $24.86M | N/A | 22.45 | 9.70 | 5.59 |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.10M | -0.29 | -0.41 | -1.95 | -2.99 |
| LeonaBio, Inc. (LONA)vs › | $22.80M | -32.78 | -24.95 | -26.53 | -21.18 |
| Seres Therapeutics, Inc. (MCRB)vs › | $29.10M | -2.41 | -9.11 | -20.57 | -19.82 |
| GridAI Technologies Corp. (GRDX)vs › | $28.20M | -4.31 | -4.75 | -350.99 | -43000.60 |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.22M | -1.66 | -1.66 | -2.82 | -25.82 |
| aTyr Pharma, Inc. (ATYR)vs › | $28.70M | -0.62 | -0.83 | -1.05 | -1.29 |
| CervoMed Inc. (CRVO)vs › | $30.00M | -3.21 | -2.50 | -4.25 | -9.67 |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.23M | N/A | -0.24 | -0.01 | 0.39 |
Trailing EPS (TTM)
$-4.34
Forward EPS (Est.)
$-3.75
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -4.04 |
| 2024-12-31 | -3.00 |
| 2023-12-31 | -3.60 |
| 2022-12-31 | -3.15 |
| 2021-12-31 | -2.70 |
| 2020-12-31 | -29.55 |
| 2019-12-31 | -30.45 |
| 2018-12-31 | -82.50 |
| 2017-12-31 | -164.55 |
| 2016-12-31 | -388.95 |
| 2015-12-31 | -1433.10 |
| 2014-12-31 | -1646.40 |
| 2013-12-31 | -1880.55 |
| 2012-12-31 | -1101.45 |
| 2011-12-31 | -1019.40 |
| 2010-12-31 | -494.40 |
| 2009-12-31 | -36.30 |
